

THE ANTI-ANGIOGENIC BASIS OF METRONOMIC CHEMOTHERAPY

Robert S. Kerbel and Barton A. Kamen[‡]*

In addition to proliferating cancer cells and various types of normal cells, such as those of the bone marrow, conventional cytotoxic chemotherapeutics affect the endothelium of the growing tumour vasculature. The anti-angiogenic efficacy of chemotherapy seems to be optimized by administering comparatively low doses of drug on a frequent or continuous schedule, with no extended interruptions — sometimes referred to as ‘metronomic’ chemotherapy. In addition to reduced acute toxicity, the efficacy of metronomic chemotherapy seems to increase when administered in combination with specific anti-angiogenic drugs. Gaining better insight into the mechanisms of these effects could lessen or even eliminate the empiricism used to determine the optimal dose and schedule for metronomic chemotherapy regimens.

For almost half a century, systemic therapy of cancer has been dominated by the use of cytotoxic chemotherapeutics. Most of these drugs are DNA-damaging agents or microtubule inhibitors that are designed to inhibit or kill rapidly dividing cells. They are often administered in single doses or short courses of therapy at the highest doses possible without causing life-threatening levels of toxicity — this is referred to as the ‘maximum tolerated dose’ (MTD). MTD therapy requires prolonged breaks (generally of 2–3 weeks in duration) between successive cycles of therapy. Despite the number of such chemotherapeutics and the huge number of clinical trials that have been undertaken to test them, progress has been modest in terms of curing or significantly prolonging the lives of patients with cancer — particularly those with advanced-stage or metastatic disease^{1,2}. Moreover, the progress that has been made in treating certain types of malignancy often comes at a high price, given the toxic side effects that are frequently associated with MTD-based chemotherapy. These include acute myelosuppression, hair loss, damage to the intestinal mucosa, nausea and mucositis, as well as the long-term cardiac, renal, neurological and reproductive consequences. Indeed, many of the recent pharmacological advances in oncology treatment involve growth factors

and anti-nausea drugs, which are administered to patients with cancer to minimize the severity of, or accelerate recovery from, chemotherapy-induced toxicities. Such ‘supportive-care drugs’ can significantly add to the financial burden of cancer chemotherapy, and have their own side effects.

A reappraisal of the best ways of administering chemotherapy is underway. Instead of only using short bursts of toxic MTD chemotherapy interspersed with long breaks to allow recovery from the harmful side effects, there is now a shift in thinking towards the view that more compressed or accelerated schedules of drug administration using much smaller individual doses than the MTD would be more effective — not only in terms of reducing certain toxicities, but perhaps even improving antitumour effects as well^{3–6}. Moreover, some of these dosing/scheduling strategies are ideally suited to combining chemotherapeutics with many of the new targeted and relatively non-toxic anticancer drugs that have been or are being developed. The most recent refinement of this concept is called ‘metronomic’ chemotherapy³, which refers to the frequent, even daily, administration of chemotherapeutics at doses significantly below the MTD, with no prolonged drug-free breaks.

**Molecular and Cellular Biology Research, Sunnybrook and Women's College Health Sciences Centre, S-217, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada.*
[‡]*Cancer Institute of New Jersey, Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, NJ 08901, USA.*
 Correspondence to R.S.K.
 e-mail: RSKerbel@aol.com
 doi:10.1038/nrc1369

Summary

- Conventional cytotoxic anticancer drugs have anti-angiogenic effects, which could contribute to their antitumour efficacy.
- The anti-angiogenic effects of chemotherapy seem to be optimized by administering such drugs ‘metronomically’ — in small doses on a frequent schedule (daily, several times a week, or weekly) in an uninterrupted manner, for prolonged periods.
- Conventional chemotherapy, which is administered at more toxic ‘maximum tolerated doses’, requires 2–3-week breaks between successive cycles of therapy. This seems to counteract the potential for sustained, therapeutically effective anti-angiogenic effects.
- In preclinical models, metronomic chemotherapy can be effective in treating tumours in which the cancer cells have developed resistance to the same chemotherapeutics. This also has the advantage of being less acutely toxic, therefore making more prolonged treatments possible.
- The efficacy of metronomic chemotherapy can be significantly increased when administered in combination with anti-angiogenic drugs, such as antibodies against vascular endothelial growth factor (VEGF) or VEGF receptor 2.
- Some metronomic-chemotherapy regimens induce sustained suppression of circulating endothelial progenitor cells and increase the levels of the endogenous angiogenesis inhibitor thrombospondin 1, both of which can suppress neovascularization.
- Clinical trials are under way to test several combinations of metronomic chemotherapy and anti-angiogenic drugs.

Metronomic therapy

There are many different factors that have contributed to the line of reasoning that for chemotherapy, ‘the more frequent the better’ and that ‘less is more’. First, the opposite approach — using ‘high-dose’ chemotherapy with autologous bone-marrow stem-cell transplants (to replace the destroyed bone-marrow-derived stem cells) — has not provided the kind of survival benefits expected, at least when this treatment strategy is used for patients with metastatic breast cancer^{7,8}. This approach is also very expensive and highly toxic. Furthermore, ‘dose-dense’ chemotherapy, in which one or more chemotherapeutic is administered at more frequent intervals (that is, every other week), has shown clear benefits in randomized Phase III clinical trials^{9–11}. This strategy is usually designed to administer at least the same amount or, more commonly, even a greater amount of drug in total over time.⁹

So, if every other week is better than every 3 weeks, then why not administer weekly or even daily treatment? Indeed, it is becoming more common to administer taxane drugs to patients with certain types of cancer, such as **breast cancer**, on a weekly schedule^{12–15}. Such dose density — which is allowable because of exogenously administered supportive-care growth factors, antibiotics and transfusion medicine — seems in some respects to be conforming to the metronomic-therapy theme, as discussed below.

METRONOMIC CHEMOTHERAPY can be viewed as a variation of dose-dense therapy with the exception that the cumulative dose with metronomic therapy might be significantly less than with MTD-based chemotherapy^{15–16}. As metronomic therapy reduces the level of toxicity, it lessens or even removes the need for growth-factor support to accelerate recovery from myelosuppression. Moreover, despite lower cumulative

doses of drug administration, the antitumour effects of this approach, in terms of prolonging survival times, might actually be superior to conventional MTD regimens, especially in some preclinical models^{17–19}. Support for metronomic therapy also comes from mathematical modelling studies^{20,21}. Unlike dose-dense chemotherapy, the main targets of which are presumed to be proliferating tumour cells, the main targets of frequent or continuous metronomic chemotherapy are the endothelial cells of the growing vasculature of a tumour²². In essence, chemotherapeutics are used as anti-angiogenic agents, therefore “redefining the target of chemotherapy”, to cite Miller *et al.*²³. This is also the reason that Browder *et al.*²² coined the term ‘anti-angiogenic chemotherapy’ to describe this treatment strategy.

Another advantage of metronomic chemotherapy is the possibility of combining it with anti-angiogenic drugs, as well as other types of targeted therapies — such those that target specific signal-transduction molecules — or with antitumour vaccines. It is ironic that targeted therapies were originally designed with the goal of replacing chemotherapy, to reduce the serious morbidities associated with standard MTD or high-dose chemotherapy. However, although they are less toxic, most of these rationally designed drugs were found to have very modest efficacy, at least when used as single agents in treating patients with advanced disease. They have therefore mainly been used in combination with standard chemotherapy or radiation protocols. An example of this is bevacizumab (Avastin) — a humanized monoclonal antibody against vascular endothelial cell growth factor (VEGF) — which is used in combination with 5-fluorouracil (5-FU)/leucovorin/irinotecan for the treatment of metastatic **colorectal cancer**^{24,25}. Another example is trastuzumab (Herceptin) — a humanized monoclonal antibody against the **ERBB2** oncoprotein — which is combined with an alkylating agent or paclitaxel for the treatment of metastatic breast cancer²⁶.

One of the proposed benefits of targeted therapies was reduced toxicity and improved quality of life. When these drugs are combined with MTDs of chemotherapy, however, these benefits are not realized. As it is likely that chemotherapy will continue to be the mainstay for systemic cancer therapy for many years to come, designing more effective ways of administering and combining such drugs with the newest generation of molecularly targeted drugs will become increasingly crucial.

Anti-angiogenic effects

Chemotherapeutics do not specifically target tumour cells, but rather interfere with cell division, such as by inhibiting enzymes involved DNA replication or metabolism (for example, topoisomerases and thymidylate synthase), or microtubules. These drugs therefore also damage the normal dividing cells of rapidly regenerating tissues, such as those of the bone marrow and gut mucosa, and hair-follicle cells. Host toxicity is therefore often only marginally less than antitumour efficacy, so creating a narrow therapeutic index.

METRONOMIC CHEMOTHERAPY
Chronic administration of chemotherapy at relatively low, non-toxic doses on a frequent schedule of administration, with no prolonged drug-free breaks.

a MTD pulsatile chemotherapy (every 3 weeks)**b Metronomic chemotherapy – lower dose on a weekly basis****c Metronomic chemotherapy – lower dose on a daily basis**

Figure 1 | Different therapeutic regimens. Metronomic chemotherapy regimens differ from the standard maximum tolerated dose (MTD) chemotherapy regimens that have been common practice in medical oncology for decades. **a** | In standard chemotherapy, a drug is typically given in a single bolus injection or infusion at the MTD, interspersed by a long break — for example, 3 weeks — before the next course of this therapy is administered. Doses that exceed the MTD ('high-dose' chemotherapy) must be accompanied by an autologous bone-marrow stem-cell transplant and supportive-care growth-factor drugs to prevent lethal bone-marrow failure. In **b** and **c**, examples of metronomic chemotherapy regimens are shown where, for example, the chemotherapy drug is administered more frequently, such as weekly (**b**) or daily (**c**), with no prolonged drug-free interruptions. Drugs that can be administered orally, such as cyclophosphamide, capecitabine, etoposide (VP-16), UFT (uracil plus tegafur, a fluoropyrimidine antimetabolite), would be ideal for prolonged daily administration schedules. Omission of prolonged drug-free periods is a key aspect of the basis for the anti-angiogenic effects of low-dose metronomic chemotherapy regimens, as these breaks allow repair and recovery from the anti-angiogenic effects of chemotherapy drugs on developing tumour blood vessels.

But perhaps there is a silver lining in this otherwise dark cloud, in that dividing endothelial cells are present in the growing blood vessels that are found in tumours²⁷ and, like other normal dividing cells, should be susceptible to chemotherapeutics²⁸. Elimination of these dividing endothelial cells, or inhibition of their division, would presumably lead to an anti-angiogenic effect. Moreover, as host vascular endothelial cells are assumed to be genetically stable and lack the diverse genetic defects characteristic of cancer cells that lead to drug resistance, the putative effects of chemotherapy might be more durable in the face of continued therapy. By way of example, successive cycles of MTD-based chemotherapy can cause myelosuppression each time, the extent of which does not change appreciably²⁸. If normal bone-marrow-cell progenitors acquired resistance to chemotherapy in the same way that genetically unstable, highly mutable cancer cells do, myelosuppression would gradually decline and disappear. So, the cancer cells that are resistant to a particular chemotherapeutic agent might indirectly respond to that same drug through a 'side effect' — loss of or damage to its associated vasculature, as first proposed in 1991 (REF. 29). Literature dating back to the mid-1980s shows that virtually every class of chemotherapeutic has anti-angiogenic effects or antivascular effects in various *in vitro* and *in vivo* assays²³.

Many tumours, however, are intrinsically drug resistant or rapidly acquire resistance after showing initial responsiveness to chemotherapy regimens. So it would

seem that chemotherapy has minimal or negligible anti-angiogenic effects. Why is this? Perhaps the proportion of dividing endothelial cells in tumour-associated blood vessels is simply too low for chemotherapy to have a significant therapeutic impact. Alternatively, the endothelial cells might be protected from chemotherapy-induced cell death by high local concentrations of endothelial-cell survival factors such as VEGF, basic fibroblast growth factor (bFGF) and **angiopoietin 1** (REFS 30,31). A third explanation, uncovered in a pioneering study from Judah Folkman's laboratory²², is that the anti-angiogenic effects of chemotherapy are both masked and marginalized by the way chemotherapy is usually administered. In this case, the long breaks between drug administration that are necessary to allow the patient to recover from the harmful side effects of the MTD chemotherapy, especially from myelosuppression, reduce the anti-angiogenic effects of the drugs.

Timothy Browder and colleagues evaluated the anti-angiogenic and antitumour effects of the alkylating agent cyclophosphamide in immune-competent syngeneic mice that had been injected subcutaneously with various tumour types²². They found that this drug, when administered at the MTD, caused apoptosis of endothelial cells in the newly formed tumour microvessels²². A detailed temporal analysis showed that the endothelial cells were the first in the tumour to undergo apoptosis²². This anti-angiogenic effect did not, however, translate into a significant therapeutic benefit, apparently because the damage to the vasculature of the tumour was largely repaired during the long (2–3-week) rest/recovery periods between successive cycles of MTD-based therapy.

It was therefore proposed that if cyclophosphamide was given more frequently (FIG. 1), such as once or more per week with no extended breaks, there would be significantly less opportunity for repair of the damaged endothelium and the anti-angiogenic effects of the chemotherapy would irreversibly accumulate. This, of course, necessitates lowering the dose of the drug administered with each injection. Browder *et al.* showed that this more frequent, regular, lower-dose therapy, which was administered at one-third of the MTD, had impressive anti-angiogenic and antitumour effects when tested on several mouse tumour cell lines grown subcutaneously in syngeneic mice²². This approach allowed even very large established subcutaneous tumours, previously selected *in vivo* for acquired cyclophosphamide resistance using a conventional MTD regimen, to respond to the same drug and almost completely regress. In short, a state of acquired drug resistance could be reversed simply by apparently shifting the focus of the treatment away from the drug-resistant cancer-cell population to the drug-sensitive tumour endothelium^{3,22}.

These results have been confirmed by others^{32,33} and have also been modified with daily oral administration of the drug through drinking water, which seems to be less toxic than the weekly regimen^{19,34}. Indeed, a recent detailed analysis showed that long-term daily low-dose cyclophosphamide therapy did not cause significant

toxicity to tissues or cells normally affected by MTD regimens of the same drug³⁵; lymphopaenia was the only toxic side effect noted³⁵.

Clinical precedents for metronomic therapy

In retrospect, these preclinical results actually have many intriguing clinical precedents^{4,36}. For example, 40% of patients with **non-small-cell lung cancer** (NSCLC) who showed no response to standard doses of intravenous etoposide administered intermittently did respond — that is, their tumours shrank by 50% of more in volume — to the same drug when it was given orally at a much lower dose using a much more frequent basis (every day or every other day), with only a 1-week break every month³⁷. Similar results have been shown in patients who have been given other drugs, such as microtubule-inhibiting taxanes, for treatment of advanced metastatic breast or **ovarian cancer**. In these patients, weekly regimens of drug administration are being increasingly adopted, often using only 30–40% of the MTD given once every 3 weeks³⁸. In women who had stopped responding to the MTD of paclitaxel or docetaxel given once every 3 weeks, tumours were found to respond in a high proportion of cases to a regimen of approximately 30–40% the MTD once every week^{13,36,38–40}. However, for the most part, these are not standard-of-care regimens and their benefits remain to be validated in randomized prospective Phase III clinical trials.

Metronomic therapy is also similar in many ways to the various long-term ‘maintenance’ chemotherapy regimens^{41–45} that are used to treat children with certain types of cancer, such as **acute lymphoblastic leukaemia**. Maintenance therapy in this case involves the administration of low doses of oral methotrexate on a weekly basis and 6-mercaptopurine on a daily basis for up to 3 years. This treatment follows short-term remission-inducing chemotherapy using standard regimens and higher doses of various chemotherapeutic drugs^{42,45}. Several studies have indicated that the drugs used in this type of maintenance therapy have anti-angiogenic effects^{46–48}. In the case of methotrexate, low doses have been shown to cause anti-endothelial/anti-angiogenic effects in *in vitro* and *in vivo* assays^{46,47}. Furthermore, the maintenance therapy used to treat patients with acute lymphoblastic leukaemia has been shown to have anti-angiogenic effects in the bone marrow, reducing the number of blood vessels in this tissue compartment^{49–51}. The success of following standard MTD ‘remission-induction’ chemotherapy with long-term metronomic therapy regimens highlights the possibility that these two types of dosing regimens are not mutually exclusive, but can be used sequentially in a beneficial and harmonious manner. This approach should also be considered for adults, especially when combined with a cytostatic agent for long-term therapy.

Combination with anti-angiogenic drugs

Clinical trials are underway to determine whether metronomic chemotherapy can prolong survival when compared with standard MTD regimens in patients

with various cancers, including advanced **prostate** and ovarian carcinomas, as well as certain types of haematological malignancies^{6,49–52}. Relapses, however, will undoubtedly occur in most patients who initially show some benefit from metronomic therapy⁴⁹. It was partly for this reason that the metronomic-chemotherapy protocol of Browder *et al.* has been modified and combined with endothelial-cell-specific angiogenesis inhibitors such as anti-VEGF receptor 2 (**VEGFR2**, also known as KDR or FLK1) antibodies or TNP-470, a fumigillin analogue^{22,53}. This combination approach might improve efficacy without significantly increasing host toxicity¹⁶.

The rationale for this strategy was based on several considerations. VEGF-receptor tyrosine kinases are expressed preferentially by endothelial cells of the growing neovasculature of a tumour, and VEGF is a key survival (anti-apoptotic) factor for the endothelial cells of newly formed vessels^{54,55}. There are several signalling pathways and molecular effector mechanisms by which VEGF can inhibit apoptosis in endothelial cells^{31,56–60}. For example, signalling through VEGFR2 can activate the phosphatidylinositol 3-kinase (PI3K)–AKT pro-survival signalling pathway. This or other pathways lead to subsequent upregulation of several anti-apoptotic effectors, including BCL2, A1, XIAP and survivin³¹.

There is evidence that the anti-proliferative³⁰ or pro-apoptotic actions of paclitaxel³¹, vinblastine, cisplatin and adriamycin³¹, as well as of several other types of cytotoxic substances, on human endothelial cells in culture are suppressed by the presence of VEGF^{30,31}. High local concentrations of VEGF in the tumour microenvironment might therefore induce or promote multidrug resistance, by inducing a highly specific chemoprotective effect towards the VEGFR2-positive endothelial cells of the tumour^{30,31,61}. Chemotherapy itself might also induce or upregulate the expression of VEGF and other endothelial-cell pro-survival growth factors in tumour cells⁶². So, the combination of a chemotherapeutic agent with a drug that blocks VEGF or its receptor (VEGFR2) should selectively amplify the pro-apoptotic effects of the chemotherapeutic against activated endothelial cells, but presumably not against other types of dividing normal cells¹⁶. This would improve the therapeutic index.

Previous studies have shown that anti-angiogenic drugs can improve the effects of some standard chemotherapy regimens^{63,64}, and these findings have been validated in the clinic^{24,25}. For example, in a large, randomized, placebo-controlled Phase III clinical trial, the combination of a standard, approved chemotherapy regimen for metastatic colorectal cancer — consisting of 5-FU/leucovorin and irinotecan — with bevacizumab (the anti-VEGF antibody), caused a statistically significant prolongation of survival, compared with patients treated with only the chemotherapy regimen²⁵. So, one might anticipate that anti-angiogenic drugs should also improve the efficacy of continuous low-dose chemotherapy regimens, for which the side effects would be much more tolerable, and that the two types of drug could be administered together for long time periods.

Experiments were undertaken to evaluate this combination treatment concept using xenograft models of neuroblastoma¹⁶, melanoma, breast, prostate and colon cancers^{19,65}. In one of these studies, a very low dose of vinblastine was administered twice weekly — which was about 1/10–1/20 the MTD for mice and therefore represents low-dose chemotherapy^{66,67} — in combination with an anti-VEGFR2 blocking monoclonal antibody called DC101 (REF. 70). This combination caused complete and sustained regression of large, established — but localized — neuroblastoma xenografts in severe combined immunodeficient (SCID) mice. The metronomic vinblastine treatment was preceded by a 3-week remission-induction schedule of higher cumulative doses of the drug¹⁶ to reduce the large tumour burden. This combination treatment, in which the two different drugs were given twice a week with no breaks, could be maintained for these exceptionally long periods (7 months) because they were not toxic to the mice¹⁶. By contrast, treatment with either the vinblastine regimen or DC101 alone, although non-toxic, resulted in significant but short delays in the growth of the tumour in the growth followed by relapse, and the animals only survived 1–2 months after initiation of treatment.

Were the low-dose chemotherapy regimens used in these studies anti-angiogenic and, if so, was this was the only antitumour mechanism? To address this question, a quantitative *in vivo* blood-vessel PERFUSION ASSAY showed that the low-dose vinblastine protocol itself could significantly inhibit angiogenesis¹⁶. Similarly, Browder *et al.* tested the weekly low-dose cyclophosphamide regimen using a CORNEAL MICROPOCKET ASSAY to show that this metronomic therapy protocol inhibited angiogenesis²².

Other studies involved⁶⁵ human breast cancer cell lines that had been previously selected for resistance to agents such as paclitaxel, doxorubicin and vinblastine, as a result of overexpression of the multidrug resistance 1 (*MDR1*) gene, which encodes the P-glycoprotein drug-efflux pump⁶⁵. In some cases, these cells were resistant to 50–100-fold higher concentrations of drugs than normal cells⁶⁵. In xenograft studies, the combination of DC101 plus metronomic chemotherapy slowed tumour growth, whereas DC101 treatment or metronomic chemotherapy alone resulted in only temporary tumour responses — or even no apparent primary tumour responses, as measured by decreases in tumour volume. Cancer-cell-specific effects of drugs are not sufficient to overcome this level of drug resistance, so some alternative mechanism, such as anti-angiogenesis, must be involved⁶⁵. Furthermore, Browder *et al.* administered a combination of the angiogenesis inhibitor TNP470 with weekly doses of cyclophosphamide to treat large, established transplanted mouse tumours that were previously selected for resistance to cyclophosphamide. They found that the combined treatment could gradually cause marked and sustained regressions, if not complete disappearance of such tumours²².

The results of Browder *et al.* and Klement *et al.* have now been confirmed by many different groups using various empirical continuous or frequent low-dose chemotherapy regimens. These regimens included

many different chemotherapeutic drugs, as well as several different anti-angiogenic agents^{32,68–73}. A summary of the drugs, drug combinations and tumour models studied is shown in TABLE 1 (REFS 18,19,73,74). In some of these studies, an empirical metronomic dosing schedule was compared head-to-head with the respective MTD regimen of the same chemotherapeutic drug^{17,19,20,71,72}. In all cases, the MTD regimens were found to be inferior to the metronomic treatments in terms of either toxicity or survival, or both. This also held for situations in which an anti-angiogenic drug was added to the MTD, compared with respective metronomic chemotherapy regimens^{17,19,20}.

The number of such studies, however, is limited and these findings need to be confirmed using different chemotherapeutic agents. Moreover, as discussed above, there might be additional benefits to using standard MTD chemotherapy followed by a subsequent long-term metronomic regimen — especially when treating exceptionally large tumours that are known to be responsive to certain chemotherapy drugs administered in the MTD fashion. This approach was used in preclinical studies by Klement *et al.*¹⁶ and Bocci *et al.*³⁴. Whereas some of the preclinical studies reported exceptionally long-term tumour responses, and in some cases mice were even cured^{16,22}, most mice eventually relapsed^{75,76}. This indicates that some forms of acquired resistance occur — either at the host level (such as through altered drug metabolism), the tumour-cell level, (such as through selection for mutant tumour cells that can survive under the hypoxic conditions created by inhibition of angiogenesis)⁷⁵ or at the level of the endothelial cells or blood vessels (such as vascular remodelling into more mature vessels that are less responsive to anti-angiogenic treatment)⁷⁶.

Anti-angiogenic mechanisms

Much evidence, mostly *in vitro*, indicates that the ‘activated’ endothelial cells of newly forming blood-vessel capillaries are highly and selectively sensitive to very low doses of various chemotherapeutic drugs^{47,77–81}. For example, several studies have been undertaken to test the antiproliferative, migration-inhibitory and sometimes cytotoxic effects of picomolar concentrations of chemotherapeutic drugs on various human cell types, including fibroblasts, lymphocytes, tumour cells, epithelial cells from various tissues, and microvascular or macrovascular endothelial cells. A summary of some of these studies is shown in TABLE 2. Some of the most interesting studies involve various microtubule inhibitors, such as vinblastine, paclitaxel and docetaxel. In these experiments, ultra-low concentrations of these drugs were reported to inhibit proliferation or migration of endothelial cells, but not of other cell types examined. For example, Wang *et al.* reported that 10–100,000-fold higher concentrations of paclitaxel were required to inhibit proliferation and migration of human astrocytes, fibroblasts, mammary epithelial cells, keratinocytes, prostate epithelial cells or smooth-muscle cells, compared with epithelial cells⁸⁰. Taxanes, however, must be formulated in certain vehicles for injection, to

MATRIGEL-PERFUSION ASSAY OF ANGIOGENESIS

An assay that is widely used to measure angiogenesis. In this assay, an extracellular matrix gel-like plug (Matrigel) that contains angiogenic factors is implanted into the skin of mice. The new blood vessels that grow into the plug can be quantified by measuring perfusion of haemoglobin or large fluorescently tagged molecules (such as intravenously administered dextran) into the plugs.

CORNEAL-MICROPOCKET ANGIOGENESIS ASSAY

An assay for angiogenesis in which an inert polymer that contains an angiogenic growth factor, such as bFGF or VEGF, is implanted into the avascular cornea of mice or rabbits. This induces new blood vessels that can be visualized and quantified.

Table 1 | **Preclinical examples of antitumour efficacy of metronomic chemotherapy**

Tumour model	Drug combination tested	Results/comments	References
Large, established mouse tumours (EMT/6, Lewis Lung carcinoma or L1210 leukaemia)	Weekly CTX (150 mg/kg) with and without TNP-470	Regression of large drug-sensitive or resistant tumours; addition of TNP-470 required to regress drug-resistant tumours	22
Large, established s.c. (ectopic) human neuroblastoma xenografts in SCID mice	Twice per week very low-dose vinblastine (0.33 mg/kg or 1 mg/m ²) plus twice per week anti-VEGFR2 antibody (DC101) after upfront remission-induction vinblastine regimen	Sustained tumour regression with no relapse or toxicity	16
Established orthotopic multidrug resistant (P-gp-positive) human breast cancer xenografts in SCID mice	Twice per week low-dose paclitaxel or 2 times per week vinblastine, or 3 times per week cisplatinum adriamycin, with DC101 or anti-VEGFR2 antibody	Stabilization of tumours and prolonged survival in mice treated with combination therapy	65
Orthotopic human breast cancer (MDA-MB-231) xenografts in SCID mice	Daily, oral low-dose CTX (for example, ~20–40 mg/kg) plus DC101 anti-VEGFR2 antibody	Tumour stabilization or delayed growth, and prolonged survival with little toxicity	19
Advanced (late stage), bulky and spontaneous islet-cell pancreatic carcinomas arising in a mouse model of pancreatic cancer	Daily oral CTX (10 mg/kg) or twice per week vinblastine (1.5 mg/m ²) with either daily SU5416 VEGFR2 inhibitor or daily oral BA-1-12-9566 MMP inhibitor or daily i.p. BB-94 MMP inhibitor	Prolongation of survival and/or tumour regression (or stabilization), especially noted with low-dose CTX and BB-94 combination; drugs are generally ineffective as single agents	142
Orthotopic, established human U87 gliomablastoma xenograft	Frequent low-dose carboplatin and etoposide plus PEX fragment of MMP2, compared to standard chemotherapy plus PEX	Greatest survival benefit observed in low-dose chemotherapy plus PEX, and no side effects detected; severe side effects detected in higher (standard) dose chemotherapy group	18
Orthotopic human Wilms' tumour xenograft with lung metastases	Topotecan 0.36 mg/kg/day for 5 days a week, for 2 weeks and repeated, plus anti-VEGF monoclonal antibody	Only the combination treatment group found free of metastatic disease	68
Subcutaneous human breast cancer xenografts implanted into SCID-mouse-human skin chimaeras	Weekly CTX plus anti-endoglin antibody	Combination treatment was only one effective in suppression of human vessels, and was highly effective in suppressing tumour growth	96
Human soft-tissue sarcoma xenografts in SCID mice	Doxorubicin administered every 3 days and DC101 anti-VEGFR2 antibody twice per week	Most effective and least toxic treatment consisted of low-dose chemotherapy plus DC101 antibody	70
Human testicular germ-cell tumour xenografts	Low-dose cisplatinum on days 14 and 21 plus daily TSP1 or endostatin	Metastatic growth affected only in combination treatment groups	71

Metronomic chemotherapy was used in combination with anti-angiogenic drugs. CTX, cyclophosphamide; i.p., intraperitoneal; MMP, matrix metalloproteinase; P-gp, P-glycoprotein; s.c., subcutaneous; SCID, severe combined immunodeficient; TSP1, thrombospondin 1; VEGF, vascular endothelial growth factor; VEGFR2, VEGF receptor 2.

prevent their binding to serum proteins. Clinically relevant concentrations of these vehicles or binding proteins can significantly dampen the anti-angiogenic activity of taxanes, meaning that higher doses of such injectable taxanes would have to be used *in vivo* to induce anti-angiogenic effects⁸².

Most of these studies reported no cytotoxic effects, although we have found that if endothelial cells are continuously exposed to a low concentration of drug such as paclitaxel over a 6 day period (replicating metronomic therapy), endothelial cells, but not dermal fibroblasts or tumour cells, undergo apoptosis within about 5 days⁷⁸. This delay in cytotoxicity indicates that

the pro-apoptotic effects of low-dose metronomic chemotherapy on endothelial cells might not be direct, but could instead be a secondary result of some other process that is specific to the vascular endothelial cell. This concept is illustrated in FIG. 2.

Two recent studies implicate thrombospondin 1 (TSP1) as a potential mediator of the effects of metronomic cyclophosphamide^{33,34}. In one study, 5 days of exposure to low concentrations of various chemotherapeutic drugs caused a marked increase in TSP1 mRNA and protein levels in vascular endothelial cells *in vitro* (other cells were not tested). TSP1, a component of the extracellular matrix that can also be secreted and found

Table 2 | **Sensitivity of human vascular endothelial cells to metronomic therapy**

Drug(s)	Assay(s)	Results	References
Methotrexate	Inhibition of cell proliferation	Human endothelial cells inhibited by low concentrations of drug (5×10^{-9} M)	47
Paclitaxel	Inhibition of endothelial-cell proliferation, motility and cord/tube formation	Inhibition of endothelial-cell chemotoxins and invasiveness detected after several hours incubation with drug concentrations as low as 10 pM ($IC_{50}^* = 0.5\text{--}4$ nM)	77
Vinblastine	Inhibition of proliferation and migration and inhibition of metalloproteinase secretion	Human endothelial cells inhibited by ultra-low concentrations (0.1–1 pM/l); leukocytes, fibroblasts and tumour cells not inhibited	79
Paclitaxel and vinblastine	Inhibition of endothelial- or tumour-cell proliferation in monolayer or tumour spheroid culture (for tumour cells)	Human umbilical endothelial cells inhibited with IC_{50} values in the range of 0.4–0.5 nM; tumour cells inhibited by IC_{50} values in the range of 2–27 nM in monolayer culture, and 3,434–10,084 nM in spheroid culture	65
Paclitaxel, cyclophosphamide and epothilone B	Inhibition of cell proliferation and induction of apoptosis, testing human endothelial cells, fibroblasts and tumour cells	Daily exposure to drugs over 6 days resulted in inhibition of human endothelial-cell proliferation with IC_{50} values in the range of 50–100 pM; IC_{50} values for tumour cells or fibroblasts were generally at least 10 times more than for endothelial cells; induction of apoptosis only detected in endothelial cells	78
Paclitaxel	Inhibition of cell proliferation and endothelial-cell tube formation	Paclitaxel (over three days) selectively inhibits proliferation of human endothelial cells at ultra-low concentrations (0.1–100 pM) with an IC_{50} value of 0.1 pM; six different non-endothelial cell types inhibited at $10^4\text{--}10^5$ -fold higher concentrations ($IC_{50} = 1\text{--}10$ nM); endothelial-cell tube formation also inhibited <i>in vitro</i>	80
Paclitaxel and docetaxel	Inhibition of cell proliferation, migration and capillary sprouting	Endothelial cells found to be 10–100 times more sensitive than tumour cells; docetaxel 10 times more effective than paclitaxel	81

In vitro studies were performed with low doses of chemotherapeutic drugs. *The IC_{50} (inhibitory concentration 50%) is the concentration of drug required to inhibit 50% of cell growth.

in the circulation, is a well known endogenous inhibitor of angiogenesis^{83,84}. It seems to act primarily by binding to CD36 receptors, which are expressed by endothelial cells⁸⁵. This interaction blocks proliferation and induces apoptosis in endothelial cells^{86,87}, but would not be expected to occur in CD36-negative cells, such as most bone-marrow-derived haematopoietic stem cells or hair-follicle cells. TSP1 can also bind and sequester VEGF, and therefore block its pro-angiogenic activity⁸⁸.

Further evidence to implicate TSP1 as a secondary mediator of the anti-angiogenic properties of metronomic chemotherapy was obtained in experiments that compared the anti-angiogenic and antitumour effects of MTD cyclophosphamide with a continuous daily low-dose regimen of the same drug in wild-type or *Tsp1*-null mice³⁴. In these experiments, the drug was administered continuously in the drinking water¹⁹. The antitumour efficacy (tested on subcutaneously transplanted Lewis lung carcinoma tumours) and anti-angiogenic effects were lost in the *Tsp1*-null mice, but not in the wild-type controls^{34,78}. Raghu Kalluri and collaborators have also shown that weekly administration of low doses of cyclophosphamide leads to loss of the antitumour activity of this drug against the B16 mouse melanoma grown in *Tsp1*-deficient mice³³. By contrast, the chemotherapy regimen retained its efficacy in mice that were unable to

produce either endostatin or tumstatin — two other endogenous inhibitors of angiogenesis³³. It therefore seems that these molecules are not involved in the anti-angiogenic effects of metronomic treatment with cyclophosphamide. TSP1, however, is induced in the melanoma cells and infiltrating host (stromal) cells of the treated tumours³³.

So, metronomic chemotherapy might not necessarily act directly on endothelial cells, but might instead act by inducing endothelial-cell-specific inhibitors, such as TSP1. This could explain why metronomic chemotherapy regimens do not increase the usual harmful side effects of chemotherapy, such as myelosuppression, despite the elimination or shortening of long, drug-free break periods. It is also interesting to note that other anticancer drugs that have anti-angiogenic 'side effects' could also work by a similar mechanism. For example, in 1997 trastuzumab, a monoclonal antibody against ERBB2, was implicated to have anti-angiogenic properties⁸⁹, as it inhibits VEGF expression. Furthermore, it can induce TSP1 in tumour cells⁹⁰.

As previously discussed, one crucial aspect and advantage of metronomic therapy is that it prevents the repair to the tumour vasculature that occurs between sessions of MTD therapy. What is the basis of this apparently robust and highly specific repair process?




Figure 2 | Possible mechanisms of the anti-angiogenic basis of metronomic chemotherapy. There are two routes by which metronomic chemotherapy could lead to growth arrest or apoptosis of endothelial cells in the tumour neovasculature. A ‘direct’ pathway (left) assumes that activated, differentiated endothelial cells are intrinsically sensitive to low-dose chemotherapy, for which there is some evidence^{80–85}; the same might be true for circulating endothelial progenitor cells¹⁷. The ‘indirect’ pathway (right) assumes that the levels of metronomically administered drugs are too low to induce growth arrest or apoptosis of endothelial cells. Instead, an endogenous inhibitor of angiogenesis, such as thrombospondin 1, is induced in certain cells by low-dose chemotherapy. This inhibits tumour angiogenesis and vasculogenesis, leading to a reduction in tumour neovascularization in the absence of side effects such as myelosuppression, hair loss, and nausea or vomiting.

Part of the answer might lie in the effects of metronomic chemotherapy regimens on the mobilization, levels and viability of bone-marrow-derived circulating endothelial progenitor cells (CEPs). These cells contribute to some forms of angiogenesis, such as development of the vasculature in early embryonic development, as well as tumour angiogenesis, essentially constituting a form of ‘systemic’ vasculogenesis and angiogenesis, in contrast to the local division of differentiated endothelial cells in pre-existing vessels. Until 1997, it was thought that all new endothelial cells were derived through the latter process⁹¹, but there are reports that claim that up to 50% of the endothelial cells in newly forming blood vessels come from CEPs⁹². These cells can be mobilized from the bone marrow by growth factors such as VEGF, and then enter the peripheral-blood circulation. There, they can migrate to sites of ongoing angiogenesis and differentiate into mature endothelial cells^{20,91,93}.

Bertolini *et al.*¹⁷ showed that in immune-deficient mice that were previously injected subcutaneously with human lymphoma cells, the increased levels of CEPs detected in the blood circulation of the mice sharply declined shortly after the mice were treated with a cycle of MTD cyclophosphamide. The number of these cells quickly and sharply rebounded during the drug-free break period, presumably as the result of a compensatory haematopoiesis-like effect¹⁷. By contrast, when cyclophosphamide was administered at lower doses on a weekly basis or continuously in drinking water, the numbers of CEPs gradually declined, as did their viability, and no compensatory rebound was observed¹⁷. If CEPs make a significant contribution to tumour angiogenesis — and this remains a point of continuing debate^{94,95} — the ‘rebound’ of these cells during the long break periods after MTD chemotherapy could contribute, at least in

part, to the repair process that occurs in the damaged tumour endothelium. This would explain the inability of MTD chemotherapy to inhibit tumour angiogenesis in a sustained, and therefore therapeutically effective, manner.

These studies call into question the use of growth factors as supportive measures to accelerate recovery from the myelosuppression-inducing effects of high-dose, standard MTD or dose-dense chemotherapy regimens. For example, both erythropoietin and granulocyte colony-stimulating factor (G-CSF) are often given to patients to help them recover from anaemia and myelosuppression, respectively, which are induced by MTD chemotherapy regimens. This is because they promote the mobilization of marrow progenitor cells into the peripheral circulation, where they can differentiate into mature white blood cells such as neutrophils or red blood cells, and have been shown to increase the mobilization of CEPs^{96,97}. This, in turn, can stimulate vasculogenesis/angiogenesis, leading to tumour growth^{98,99}, and could provide one explanation for the fact that treatment of patients with recombinant erythropoietin after standard chemotherapy is associated with a worse outcome, in terms of survival, in some clinical trials¹⁰⁰.

Clinical trials of metronomic chemotherapy

Phase II clinical trials have been initiated to test the possible benefits of metronomic chemotherapy regimens — particularly when these are combined with an anti-angiogenic drug. Several of these trials are summarized in TABLE 3. Most of these involve chemotherapy regimens in which cyclophosphamide is administered orally on a daily basis, sometimes for up to 2 years, with no break periods. In some cases, oral low-dose methotrexate is also given on two consecutive days on a weekly basis. The targeted drugs that are used include a cyclooxygenase-2 (COX2)-specific inhibitor such as celecoxib, which is administered on a daily basis, or a humanized anti-VEGF monoclonal antibody (such as bevacizumab), which is administered intravenously every 2 weeks. Celecoxib was selected for inclusion in the trial because of its commercial availability, ease of administration, excellent side-effect profile and putative anti-angiogenic effects^{101,102}.

The combination of cyclophosphamide and methotrexate has already been tested in a clinical trial in Italy, and has spurred additional trials that are underway⁴⁹. Sixty-four women with progressive, advanced and refractory breast cancer received low doses of oral cyclophosphamide on a daily basis and oral methotrexate was given twice per week. Most of the patients had progressive metastatic disease when the trial began and had also previously received first-, second- or third-line treatments. An overall response rate of 32% was observed, which included two complete responders, 10 partial responders and 12 patients with stable disease lasting 6 months or longer⁴⁹. No high-grade adverse events were reported, despite the fact that many patients had previously been treated with chemotherapy. This compares favorably with the standard third-line chemotherapy regimens used in

Table 3 | Clinical trials involving metronomic chemotherapy

Patient population (status of trial)	Drug treatment	References/details
Advanced, refractory melanoma; pilot study of 12 patients (completed)	Daily low-dose (500 mg) oral treosulfan and daily rofecoxib (Vioxx), 25 mg	51
Advanced, refractory prostate cancer; Phase II clinical trial of 32 patients (completed)	Daily low-dose, oral cyclophosphamide (50 mg) and daily low-dose dexamethasone (1 mg)	52
Advanced, refractory breast cancer; Phase II trial of 64 patients (completed)	Daily low-dose, oral cyclophosphamide (50 mg) and oral low-dose methotrexate twice per week	49
Advanced or metastatic ovarian carcinoma (underway)	Daily low-dose cyclophosphamide (50 mg) plus bevacizumab, 10 mg/kg every 2 weeks	A. Garcia, P.I., NCI/CTEP-sponsored multicentre Phase II clinical trial
Advanced, metastatic breast cancer (underway)	Daily low-dose, oral cyclophosphamide (50 mg), oral low-dose methotrexate twice per week (10 mg) and bevacizumab 10 mg/kg every 2 weeks	H. Burstein, P.I., Dana-Farber Cancer Institute
Recurrent and metastatic chemoresistant squamous-cell carcinoma of the head and neck (pilot study; completed)	Daily oral low-dose (2.5 mg) methotrexate and 400 mg celecoxib twice per day	139
Relapsed, refractory non-Hodgkins lymphoma (ongoing)	Oral low-dose (50 mg) cyclophosphamide and 400 mg celecoxib twice per day	140
Metastatic renal cell carcinoma (completed)	Daily oral low-dose (50 mg) cyclophosphamide and 400 mg	141
Hepatocellular carcinoma	Oral low-dose (50 mg) cyclophosphamide and 400 mg celecoxib twice per day	E. Bergsland, P.I., University of California at San Francisco
Refractory solid tumours in children and adults (completed)	Daily low-dose oral cyclophosphamide for 3 weeks followed by daily low-dose oral etoposide for 3 weeks, which is repeated chronically, combined with daily oral low-dose thalidomide and daily oral low-dose celecoxib	138
Pancreatic carcinoma	Oral low-dose (50 mg) cyclophosphamide and 400 mg celecoxib twice per day	E. Bergsland, P.I., University of California at San Francisco
Advanced metastatic breast cancer	Daily low-dose (50 mg) oral cyclophosphamide and oral low-dose methotrexate (2.5 mg) twice weekly, dalteparin (Fragmin) 5,000 IU s.c. daily and oral prednisone (5mg daily)	K. Pritchard (P.I.) <i>et al.</i> Toronto Sunnybrook Regional Cancer Centre

IU, international units; NCI/CTEP, National Cancer Institute Cancer Therapy Evaluation Program; P.I., Principal Investigator; s.c., subcutaneous.

this treatment setting, at least in terms of toxicity. The estimated cost of this outpatient therapy was about US\$10 per month⁴⁹.

In another recently reported trial, Glode *et al.* treated 32 patients with advanced androgen-independent metastatic prostate cancer. These patients received daily oral doses of cyclophosphamide and dexamethasone⁵². Dexamethasone, in addition to other properties, has been reported to have some anti-angiogenic effects⁵². In this small study, almost 70% of the patients showed a decrease in serum prostate-specific antigen levels of 50% or more. Although such preliminary results are encouraging, they need to be confirmed in much larger, controlled and prospective clinical trials¹⁰³.

It is also very difficult to determine conclusively whether these therapies have anti-angiogenic effects that contribute to their putative antitumour efficacy. In this regard, Colleoni *et al.* reported that serum VEGF levels declined in patients who responded to therapy⁴⁹. Bertolini *et al.* reported a reduced number of bone-marrow-derived CEPs in the blood of patients

with lymphoma and breast cancer who received daily low-dose cyclophosphamide therapy¹⁰⁴, similar to that observed in patients with rectal carcinoma who are treated with the anti-VEGF monoclonal antibody bevacizumab¹⁰⁵. Nevertheless, the therapies obviously have other effects that contribute to their efficacy — this is especially true for drugs such as celecoxib and dexamethasone. For example, COX2, which is inhibited by celecoxib, can be expressed by tumour cells as well as by activated endothelial cells¹⁰¹. It is also known that low-dose chemotherapy, can stimulate the immune system in some cases,^{106,107} making it a potentially useful addition in combination with tumour vaccines or other types of immune-therapy approaches. Indeed, some studies indicate that metronomic chemotherapy using cyclophosphamide can increase the efficacy of immunotherapeutic vaccines in preclinical models^{108,109}.

Metronomic therapy might also have some direct effects on tumour cells, such as induction of cell differentiation, although there is not yet any evidence for this. Continuous-chemotherapy regimens could also

Table 4 | **Metronomic chemotherapy in paediatric oncology**

Disease	Drug(s)	References
Lymphoma	'CHOP' (cyclophosphamide, doxorubicin, vincristine and prednisone)*	41
Acute lymphatic leukaemia	Methotrexate and 6-mercaptopurine†	42,45
Wilms' tumour	Vincristine‡	44
Rhabdomyosarcoma	Vinblastine and actinomycin, or vincristine, actinomycin and cyclophosphamide§	43

*Induction remission: (days 1–47), vincristine, 1.5 mg/m², weekly for 7 weeks (maximum dose, 2.0 mg), cyclophosphamide, 750 mg/m² intravenously on days 1, 22 and 43; doxorubicin (adriamycin) 40 mg/m² intravenously on days 1, 22, and 43; prednisone 40 mg/m², oral, days 1–28, and then days 43–47. †Methotrexate 20–50 mg/m²/week for up to 2 years and 6-mercaptopurine, 50–75 mg/m² daily for up to 2 years; all protocols, but this is the range. ‡Vincristine: same dose for treatment of patients with lymphoma (1.5 mg/m²) weekly for 10 weeks and then on weeks 12, 15 and 18. §Vincristine 1.5 mg/m², weekly for 7 weeks as part of a combination chemotherapy regimen; for example, vincristine, actinomycin and cyclophosphamide, which may be given weekly for 13 weeks, with a 4 week break, and weekly for 8 weeks, followed by a 3 week break and then 12 of the next 17 weeks.

prevent a rebound in tumour-cell division known as 'repopulation', which can take place during the rest periods between cycles of MTD chemotherapy. Repopulation kinetics can become increasingly more aggressive with successive cycles of MTD pulsatile chemotherapy¹¹⁰, so shortening or eliminating the drug-free break periods might prevent this 'kinetic drug resistance'.

Several successful paediatric chemotherapy approaches resemble metronomic therapy, as discussed above, in that they involve daily administration of low doses of cytotoxic drugs over prolonged periods of time, as so-called 'maintenance' therapies, and have minimal toxicity (TABLE 4). Paediatric oncologists have shown that daily administration of cyclophosphamide along with weekly administration of *Vinca* alkaloid drugs, such as vincristine or vinblastine, is effective in treating patients with diseases such as neuroblastoma¹¹¹. Weekly administration of *Vinca* alkaloids is also a key component of therapy for patients with **Wilms' tumour** and **rhabdomyosarcoma**. Paediatric 'CHOP' (cyclophosphamide, adriamycin, vincristine and prednisone) therapy, which is used to treat patients with **non-Hodgkin's lymphoma**, is also conceptually similar to metronomic therapy. Aggressive fibromatosis can also be controlled with low-dose vinblastine and methotrexate treatment¹¹². Other low-dose chemotherapy regimens that are being tested in children, with some hints of success, include low-dose cyclophosphamide treatment and low-dose vincristine therapy to treat infants with localized, unresectable neuroblastoma¹¹¹.

The oral fluoropyrimidine¹¹³ agent, UFT (uracil plus tegafur) — a prodrug mixture that is metabolized to 5-FU and two other metabolites, γ -butyrolactone (GBL) and γ -hydroxybutyric acid (GHB) — represents another chemotherapeutic that might be applied metronomically^{74,111,114}. This drug is approved for treatment of certain cancers in Japan and throughout Europe, but not in the United States¹¹⁵. Recent randomized Phase III ADJUVANT clinical trials have been undertaken in patients with resected early-stage NSCLC of the adenocarcinoma variety. These patients

were given daily low doses of oral UFT for 2 years, resulting in both a survival benefit and very little toxicity, despite the chronic nature of the treatment¹¹⁶. 5-FU, GBL and GHB have all been shown to have anti-angiogenic activity in an *in vivo* assay^{74,117}, as well as to inhibit growth and migration of endothelial cells in culture^{74,117} — especially when they are administered continuously at low doses⁷⁴. Could the anti-angiogenic effects of this drug contribute to its clinical efficacy? Could this efficacy be increased by combination therapy with a targeted anti-angiogenic drug? Further studies are necessary to answer these questions. The trial of UFT in patients with lung cancer, however, shows the potential of oral long-term metronomic chemotherapy as an adjuvant therapy to treat patients who could have microscopic, early-stage recurring tumours.

Further experiments are required to determine whether other chemotherapeutics that can be orally administered on daily schedules for extended periods of time, such as the topoisomerase enzyme inhibitor etoposide (VP-16) or the alkylating agent temozolamide¹¹⁸, also have anti-angiogenic effects¹¹⁹ that contribute to their antitumour efficacy. There are several other situations in which prolonged oral administration (4–5 weeks) of relatively low doses of chemotherapeutics is already in use, such as administration of etoposide^{37,120}, razoxane¹²¹ or temozolamide^{122,123} to treat malignant melanoma and non-Hodgkin's lymphoma. These are palliative-like regimens that are less toxic and are sometimes used to treat elderly patients, who are less able to cope with toxic MTD chemotherapy. It will be important to determine if anti-angiogenic effects contribute to the efficacy of such protocols — there is already some preliminary evidence that this is the case^{119,121}. These studies could also accelerate the development of oral taxanes and other microtubule inhibitors for metronomic therapy¹²⁴. Another approach involves the use of injectable chemotherapeutics that are incorporated into endothelial-targeted liposomes to increase the half-life of the drug in the circulation¹²⁵.

Other types of metronomic therapy

The metronomic approach is not only used with chemotherapy, but also with radiation therapy. Sometimes, radiotherapy is administered at lower than normal doses, known as 'hyperfractionated radiation'⁹². In this regard, Garcia-Barros *et al.* have shown that the antitumour effects of irradiation can be mediated through a primary event that involves damage or destruction of the neovasculature of a tumour, followed by the death of tumour cells that surround the affected vessels⁹². This could help to explain the increased therapeutic efficacy of combining radiation therapy with endothelial-cell-specific anti-angiogenic drugs such as angiostatin or anti-VEGF antibodies^{126,127}.

The cytokine interferon- α (IFN- α) also has anti-angiogenic effects, and is used effectively to treat paediatric patients with haemangiomas or giant-cell tumours when administered in small daily doses over prolonged periods of time^{128,129}. This might be considered to be another example of the efficacy of anti-angiogenic

ADJUVANT THERAPY
Administration of certain anticancer drugs, such as tamoxifen, for prolonged periods — even as long as 3–5 years. This form of treatment is usually used to treat microscopic metastatic disease, after surgical removal of the primary tumour, or sometimes for treatments of a primary tumour, in which case it is called neoadjuvant therapy.

metronomic therapy. Preclinical studies from Isiah Fidler's group have also shown that metronomic administration of IFN- α therapy is significantly more effective as an anti-angiogenic and antitumour treatment strategy in mouse xenograft models of cancer¹³⁰. They have shown that daily administration of 10,000 units of IFN- α was more effective than 70,000 units administered once a week as an anticancer therapy¹³⁰.

Future directions

Although we have explained the potential benefits of metronomic chemotherapy regimens — especially when used in a combination-therapy context with targeted anti-angiogenic agents — there are several significant challenges that must be overcome to increase the chances of success in the clinic. Foremost among these is the current empiricism associated with trying to determine the optimal dose and schedule for administration of chemotherapeutics. Other medical subspecialties have defined minimally inhibitory concentrations, such as those used to treat patients with infectious diseases or epilepsy.

It seems that there are two main approaches to administering chemotherapy. Perhaps a useful analogy is to compare these approaches to radio airwaves. 'Amplitude modulation' (AM) involves increasing the dose, but this requires increasing the time between the doses, whereas 'frequency modulation' (FM), involves decreasing the amplitude (the unit dose/time). There are some obvious advantages to FM, such as reduced acute toxicity and the ability to combine the drug with targeted therapeutics for prolonged periods. The challenge therefore is to find the smallest dose that will control the target cells and then the most frequent dosing that will maximize this control. This type of problem is obviously not unique, as many molecularly targeted drugs do not produce their maximum therapeutic effects at the MTD, and some do not even have dose-limiting toxicities^{131,132}. Similarly, determining the biological activity of such agents in the absence of acute tumour regression can be difficult.

These problems might eventually be overcome through the discovery and application of novel molecular or functional surrogate markers, to guide dose selection and to monitor antitumour activity. The same could be the case for metronomic chemotherapy. So, detecting changes in levels of circulating TSP1 levels in serum or plasma after administration of various low doses of chemotherapeutics might be useful in determining the optimal low dose for a drug such as cyclophosphamide³⁴. Another possibility is the application of functional imaging approaches, such as those used to detect changes in tumour blood flow. For example, Walter Wolf and colleagues recently reported that administration of docetaxel on either a once-every-week schedule, or a once-every-3-weeks schedule, resulted in reductions in tumour blood flow in several patients with breast cancer, as determined by dynamic-contrast magnetic-resonance imaging. Moreover, there seemed to be a strong correlation between this change and tumour response¹³³. This is strikingly similar to the results of a clinical study involving

administration of an anti-angiogenic drug called PTK787 — a small-molecule antagonist that blocks several receptor tyrosine kinases, including VEGFR2 in patients with colorectal carcinoma¹³⁴. So, chemotherapeutics could have significant antivascular properties, which in some cases might be their primary effector function in terms of tumour destruction.

Another promising approach to determining the optimal low dose for a given metronomic chemotherapy regimen is evaluation of the activities of CEPs or circulating endothelial cells (CECs). As previously discussed, CEPs mobilization from the bone marrow into the peripheral circulation is strongly inhibited by low-dose cyclophosphamide, as is CEP viability¹⁷. So, there could be a direct relationship between the relative efficacy of different (low) doses of metronomic chemotherapy and the ability of these doses to reduce levels of CEPs in the peripheral circulation (Y. Shaked & R.S.K., unpublished observations). Furthermore, assays have been developed to detect the presence of CECs and CEPs in blood samples, such as by performing RT-PCR to detect the mRNA for the vascular endothelial cell-adhesion molecule **VE-cadherin**¹³⁵. It is therefore encouraging that infusion of bevacizumab in patients with rectal carcinoma was recently found to lead to a rapid decline of both CECs and CEPs in the peripheral blood, as these assays might be exploited not only to monitor anti-angiogenic drug or treatment activity, but to help determine the optimal dose.

A second challenge is the prospect of delayed side effects, including secondary neoplasms, when administering protracted regimens of DNA-damaging agents or other types of genotoxic agents, although it might be argued that these are not a serious concern when treating patients with advanced-stage cancers. But it is certainly a concern in adjuvant-therapy settings for patients with early-stage disease, many of whom are already cured.

As for toxic side effects, although these might be delayed, they might nevertheless be significant. We have found that mice treated with protracted daily oral low-dose cyclophosphamide can eventually develop lymphopaenia³⁵. Similarly, patients treated with extended low-dose temozolamide for successive cycles of 6 weeks with 2-week breaks can develop immunosuppressive T-cell lymphopaenia¹³⁶. In this regard, the minimal-toxicity profile observed in patients with early-stage resected NSCLC who were given low doses of UFT every day for 2 years is encouraging — grade 3 toxic effects occurred in only 10/482 (2%) of patients¹⁶. This is particularly important because anti-angiogenic drugs and metronomic chemotherapy regimens might work best, and sometimes only, in patients with low-volume disease burden. This is true for almost all anticancer drugs and treatment strategies, for various reasons. These include reduced drug access to larger tumours, as well as reduced oxygen levels (hypoxia), which can attenuate the toxic effects of radiation or chemotherapy. It might be possible to treat early-stage disease with long-term combination therapies, but this clearly necessitates the use of non-toxic and less expensive drugs.

Hopefully, some of the clinical trials that are underway, especially those that are prospective and randomized¹⁰³, will better indicate the potential promise of this therapeutic strategy — particularly when such metronomic chemotherapy regimens are integrated with new molecularly targeted drugs. In particular, there is a need to learn more about which chemotherapeutics are the most effective for metronomic dosing regimens, what combinations and sequences might be best to use, and what mechanisms of resistance might develop over time^{75,76}. Furthermore, it will be important to determine

the types of cancer that might be the most responsive to these therapeutic approaches. There is already some data available for the treatment of breast cancer¹⁵⁷ and tumours of the central nervous system¹³⁸ using this approach. As scientists carrying out basic research perform more preclinical studies this approach and begin to work more closely with clinical investigators that are leading metronomic chemotherapy-based clinical trials, there should be significant progress towards answering these questions over the next few years.

1. Schiller, J. H. *et al.* Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N. Engl. J. Med.* **346**, 92–98 (2002).
2. Leaf, C. Why we're losing the war on cancer (and how to win it). *Fortune* **149**, 77–97 (2004).
3. Hanahan, D., Bergers, G. & Bergsland, E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. *J. Clin. Invest.* **105**, 1045–1047 (2000).
An insightful commentary in which the term 'metronomic' was coined to describe prolonged therapy using frequent administration of low doses of chemotherapy as an anti-angiogenic treatment strategy.
4. Gasparini, G. Metronomic scheduling: the future of chemotherapy? *Lancet Oncol.* **2**, 733–740 (2001).
5. Kamen, B. A., Rubin, E., Aisner, J. & Glatstein, E. High-time chemotherapy or high time for low dose. *J. Clin. Oncol.* **18**, 2935–2937 (2000).
6. Kerbel, R. S., Klement, G., Pritchard, K. I. & Kamen, B. A. Continuous low-dose anti-angiogenic (metronomic) chemotherapy: from the research laboratory into the oncology clinic. *Ann. Oncol.* **13**, 12–15 (2002).
7. Nieto, Y. The verdict is not in yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer. *Haematologica* **88**, 201–211 (2003).
8. Roche, H., Viens, P., Biron, P., Lotz, J. P. & Asselain, B. High-dose chemotherapy for breast cancer: the French PEGASE experience. *Cancer Control* **10**, 42–47 (2003).
9. Piccart-Gebhart, M. J. Mathematics and oncology: a match for life? *J. Clin. Oncol.* **21**, 1425–1428 (2003).
10. Tuma, R. S. Dosing study seen as victory for clinical trials, mathematical models. *J. Natl Cancer Inst.* **95**, 254–255 (2003).
11. Citron, M. L. *et al.* Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. *J. Clin. Oncol.* **21**, 1431–1439 (2003).
12. Lokich, J. Phase I clinical trial of weekly combined paclitaxel plus docetaxel in patients with solid tumors. *Cancer* **89**, 2309–2314 (2000).
13. Burstein, H. J. *et al.* Docetaxel administered on a weekly basis for metastatic breast cancer. *J. Clin. Oncol.* **18**, 1212–1219 (2000).
14. Aihara, T., Kim, Y. & Takatsuka, Y. Phase II study of weekly docetaxel in patients with metastatic breast cancer. *Ann. Oncol.* **13**, 286–292 (2002).
15. Tulpule, A. *et al.* Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. *Cancer* **95**, 147–154 (2002).
16. Klement, G. *et al.* Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. *J. Clin. Invest.* **105**, R15–R24 (2000).
17. Bertolini, F. *et al.* Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. *Cancer Res.* **63**, 4342–4346 (2003).
A possible explanation for the repair of the tumour neovasculature during the prolonged drug-free break periods between cycles of MTD chemotherapy. Repair is mediated through mobilization of circulating endothelial progenitor cells, which is circumvented by metronomic dosing.
18. Bello, L. *et al.* Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth *in vivo*. *Cancer Res.* **61**, 7501–7506 (2001).
19. Man, S. *et al.* Antitumor and anti-angiogenic effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. *Cancer Res.* **62**, 2731–2735 (2002).
A simple, convenient and humane method of administering low doses of a drug (cyclophosphamide) on a daily basis over long periods to test metronomic chemotherapy in mouse models of cancer.
20. Hahnfeldt, P., Folkman, J. & Hlatky, L. Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. *J. Theor. Biol.* **220**, 545–554 (2003).
21. Stoll, B. R., Migliorini, C., Kadambi, A., Munn, L. L. & Jain, R. K. A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for anti-angiogenic therapy. *Blood* **102**, 2555–2561 (2003).
22. Browder, T. *et al.* Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. *Cancer Res.* **60**, 1878–1886 (2000).
A seminal study that first defined the basic principles of metronomic or 'anti-angiogenic' chemotherapy and outlined a strategy for treating drug-resistant tumours by altering the dosing and scheduling of chemotherapy, so as to target the neovasculature of the tumour more effectively.
23. Miller, K. D., Sweeney, C. J. & Sledge, G. W. Redefining the target: chemotherapeutics as antiangiogenics. *J. Clin. Oncol.* **19**, 1195–1206 (2001).
24. Hurwitz, H. *et al.* Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. *Proc. Am. Soc. Clin. Oncol.* **21**, A3646 (2003).
25. Hurwitz, H. *et al.* Addition of bevacizumab (rhuMab VEGF) to bolus IFL in the first line treatment of patients with metastatic colorectal cancer: results of a randomized phase III trial. *N. Engl. J. Med.* (in the press).
The results of a pivotal randomized Phase III clinical trial in which bevacizumab, combined with a standard chemotherapy regimen, significantly improved the survival times of patients with advanced-stage metastatic colorectal carcinoma. This trial led to the approval of bevacizumab by the Food and Drug Administration on 26 February, 2004.
26. Slamon, D. J. *et al.* Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N. Engl. J. Med.* **344**, 783–792 (2001).
27. Eberhard, A. *et al.* Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. *Cancer Res.* **60**, 1388–1393 (2000).
28. Crawford, J. *et al.* Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. *N. Engl. J. Med.* **325**, 164–170 (1991).
29. Kerbel, R. S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. *BioEssays* **13**, 31–36 (1991).
30. Sweeney, C. J. *et al.* The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. *Cancer Res.* **61**, 3369–3372 (2001).
31. Tran, J. *et al.* A role for survivin in chemoresistance of endothelial cells mediated by VEGF. *Proc. Natl Acad. Sci. USA* **99**, 4349–4354 (2002).
A study showing that VEGF can induce the equivalent of a multidrug-resistant phenotype in human vascular endothelial cells *in vitro*. This is because of the upregulation of the anti-apoptotic effector survivin when such cells are exposed to modest concentrations of the drugs in the presence of VEGF.
32. Takahashi, N., Haba, A., Matsuno, F. & Seon, B. K. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. *Cancer Res.* **61**, 7846–7854 (2001).
33. Hamano, Y. *et al.* Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. *Cancer Res.* **64**, 1570–1574 (2004).
Another important study showing that the antitumour effects of metronomic cyclophosphamide are mediated indirectly through induction of thrombospondin-1, produced by tumour cells and infiltrating stromal cells in tumours (B16 melanomas).
34. Bocci, G., Francia, G., Man, S., Lawler, J. & Kerbel, R. S. Thrombospondin-1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. *Proc. Natl Acad. Sci. USA* **100**, 12917–12922 (2003).
First study to show an indirect mechanism that accounted for the anti-angiogenic effects induced by low-dose metronomic chemotherapy. This might be a paradigm for how some other angiogenesis inhibitors work.
35. Emmenegger, U. *et al.* A comparative analysis of low dose metronomic cyclophosphamide reveals absent or low grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. *Cancer Res.* (in the press).
36. Gately, S. & Kerbel, R. Antiangiogenic scheduling of lower dose cancer chemotherapy. *Cancer J.* **7**, 427–436 (2001).
37. Kakolyris, S. *et al.* Treatment of non-small-cell lung cancer with prolonged oral etoposide. *Am. J. Clin. Oncol.* **21**, 505–508 (1998).
38. Alvarez, A. *et al.* Weekly taxol (T) in patients who had relapsed or remained stable with T in a 21 day schedule. *Proc. Am. Soc. Clin. Oncol.* **17**, A188 (1998).
39. Fennelly, D. *et al.* Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. *J. Clin. Oncol.* **15**, 187–192 (1997).
40. Greco, F. A. Docetaxel (Taxotere) administered in weekly schedules. *Semin. Oncol.* **26**, 28–31 (1999).
41. Link, M. P., Shuster, J. J., Donaldson, S. S., Berard, C. W. & Murphy, S. B. Treatment of children and young adults with early-stage non-Hodgkin's lymphoma. *N. Engl. J. Med.* **337**, 1259–1266 (1997).
42. Kamen, B. A. Why more 6-mercaptopurine? *Semin. Hematol.* **28**, 12–14 (1991).

43. Crist, W. M. *et al.* Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. *J. Clin. Oncol.* **19**, 3091–3102 (2001).
44. Grundy, P. E. *et al.* Principles and practice of pediatric oncology (eds Pizzo, P. A. & Poplack, D. G.) 865–893 (Lippincott Williams and Wilkins, Philadelphia, 2002).
45. Carnita, B. M. & Kamen, B. A. Childhood acute lymphoblastic leukemia (ed. Pui, C. H.) 357–364 (Human Press Ltd, Totowa, New Jersey, 2003).
46. Jousen, A. M., Kruse, F. E., Volcker, H. E. & Kirshhof, B. Topical application of methotrexate for inhibition of corneal angiogenesis. *Graefes Arch. Clin. Exp. Ophthalmol.* **237**, 920–927 (1999).
47. Hirata, S., Matsubara, T., Saura, R., Tateishi, H. & Hirohata, K. Inhibition of *in vitro* vascular endothelial cell proliferation and *in vivo* neovascularization by low-dose methotrexate. *Arthritis Rheum.* **32**, 1065–1073 (1989).
48. Presta, M. *et al.* Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process. *Cancer Res.* **59**, 2417–2424 (1999).
49. Colleoni, M. *et al.* Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. *Ann. Oncol.* **13**, 73–80 (2002).
- Description of a Phase II clinical trial of metronomic chemotherapy involving prolonged administration of daily oral low-dose cyclophosphamide and low-dose methotrexate, with no breaks, to treat patients with advanced metastatic breast cancer. This result has spawned several other clinical trials, many involving addition of an anti-angiogenic drug.**
50. Garber, K. Could less be more? Low-dose chemotherapy goes on trial. *J. Natl. Cancer Inst.* **94**, 82–84 (2002).
51. Spieth, K., Kaufmann, R. & Gille, J. Metronomic oral low-dose thiosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. *Cancer Chemother. Pharmacol.* **52**, 377–382 (2003).
52. Glode, L. M. *et al.* Metronomic therapy with cyclophosphamide and dexamethasone for prostate cancer. *Cancer* **98**, 1643–1648 (2003).
53. Witte, L. *et al.* Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. *Cancer Metastasis Rev.* **17**, 155–161 (1998).
54. Alon, T. *et al.* Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. *Nature Med.* **1**, 1024–1028 (1995).
55. Benjamin, L. E., Goljani, D., Itin, A., Podes, D. & Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. *J. Clin. Invest.* **103**, 159–165 (1999).
56. Gerber, H. P. *et al.* Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. *J. Biol. Chem.* **273**, 30336–30343 (1998).
57. Nor, J. E. & Polverini, P. J. Role of endothelial cell survival and death signals in angiogenesis. *Angiogenesis* **3**, 101–116 (1999).
58. Mandriota, S. J. *et al.* Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. *J. Biol. Chem.* **270**, 9709–9716 (1995).
59. Tran, J. *et al.* Marked induction of the IAP family anti-apoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. *Biochem. Biophys. Res. Commun.* **264**, 781–788 (1999).
60. Mesri, M. *et al.* Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. *Am. J. Pathol.* **158**, 1757–1765 (2001).
61. Castilla, M. A. *et al.* Role of vascular endothelial growth factor (VEGF) in endothelial cell protection against cytotoxic agents. *Life Sci.* **67**, 1003–1013 (2000).
62. Gorski, D. H. *et al.* Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. *Cancer Res.* **59**, 3374–3378 (1999).
63. Teicher, B. A., Sotomayor, E. A. & Huang, Z. D. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. *Cancer Res.* **52**, 6702–6704 (1992).
64. Kakeji, Y. & Teicher, B. A. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. *Invest. New Drugs* **15**, 39–48 (1997).
65. Klement, G. *et al.* Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug resistant human breast cancer xenograft. *Clin. Cancer Res.* **8**, 221–232 (2002).
66. Tashiro, T. *et al.* Responsiveness of human lung cancer/nude mouse to antitumor agents in a model using clinically equivalent doses. *Cancer Chemother. Pharmacol.* **24**, 187–192 (1989).
67. Inaba, M. *et al.* Evaluation of antitumor activity in a human breast tumor/nude mouse model with a special emphasis on treatment dose. *Cancer* **64**, 1577–1582 (1989).
68. Soffer, S. Z. *et al.* Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. *J. Pediatr. Surg.* **36**, 1177–1181 (2001).
69. Soffer, S. Z. *et al.* Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor. *J. Pediatr. Surg.* **36**, 1781–1784 (2001).
70. Zhang, L. *et al.* Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose Doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. *Cancer Res.* **62**, 2034–2042 (2002).
71. Abraham, D., Abri, S., Hofmann, M., Holtl, W. & Aharinejad, S. Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts. *J. Urol.* **170**, 1388–1393 (2003).
72. Svensson, A., Backman, U., Jonsson, E., Larsson, R. & Christofferson, R. CHS 828 inhibits neuroblastoma growth in mice alone and in combination with antiangiogenic drugs. *Pediatr. Res.* **51**, 607–611 (2002).
73. Petrangolini, G. *et al.* Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts. *Mol. Cancer Res.* **1**, 863–870 (2003).
74. Yonekura, K. *et al.* UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. *Clin. Cancer Res.* **5**, 2185–2191 (1999).
75. Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J. & Kerbel, R. S. Effect of p53 status on tumor response to antiangiogenic therapy. *Science* **295**, 1526–1528 (2002).
76. Huang, J. *et al.* Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. *Mol. Cancer Res.* **2**, 36–42 (2004).
77. Belotti, D. *et al.* The microtubule-affecting drug paclitaxel has antiangiogenic activity. *Clin. Cancer Res.* **2**, 1843–1849 (1996).
78. Bocci, G., Nicolaou, K. C. & Kerbel, R. Protracted low-dose effects on human endothelial cell proliferation and survival *in vitro* reveal a selective antiangiogenic window for various chemotherapeutic drugs. *Cancer Res.* **62**, 6938–6943 (2002).
- Selective inhibition of human endothelial-cell proliferation or induction of apoptosis was detected only after a prolonged exposure to very low concentrations of a number of different chemotherapeutic drugs, including taxanes and alkylating agents.**
79. Vacca, A. *et al.* Antiangiogenesis is produced by nontoxic doses of vinblastine. *Blood* **94**, 4143–4155 (1999).
- One of the first studies to show that ultra-low concentrations of the conventional chemotherapeutic drug vinblastine could selectively affect endothelial-cell functions relevant to angiogenesis.**
80. Wang, J., Lou, P., Lesniowski, R. & Henkin, J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. *Anticancer Drugs* **14**, 13–19 (2003).
- An important study showing that low concentrations of paclitaxel selectively inhibit human vascular endothelial-cell proliferation *in vitro*, whereas non-endothelial cell types were inhibited by higher drug concentrations.**
81. Grant, D. S., Williams, T. L., Zahaczewsky, M. & Dicker, A. P. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). *Int. J. Cancer* **104**, 121–129 (2003).
82. Ng, S. S., Figg, W. D. & Sparreboom, A. Taxane-mediated antiangiogenesis *in vitro*: influence of formulation vehicles and binding proteins. *Cancer Res.* **64**, 821–824 (2004).
83. de Fraipont, F., Nicholson, A. C., Feige, J. J. & Van Meir, E. G. Thrombospondins and tumor angiogenesis. *Trends. Mol. Med.* **7**, 401–407 (2001).
84. Lawler, J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. *J. Cell Mol. Med.* **6**, 1–12 (2002).
85. Dawson, D. W. *et al.* CD36 mediates the *in vitro* inhibitory effects of thrombospondin-1 on endothelial cells. *J. Cell Biol.* **138**, 707–717 (1997).
86. Guo, N., Krutzsch, H. C., Inman, J. K. & Roberts, D. D. Thrombospondin 1 and type 1 repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. *Cancer Res.* **57**, 1735–1742 (1997).
87. Jimenez, B. *et al.* Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. *Nature Med.* **6**, 41–48 (2000).
88. Gupta, K., Gupta, P., Wild, R., Ramakrishnan, S. & Hebbel, R. P. Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. *Angiogenesis* **3**, 147–158 (1999).
89. Vitoria-Petit, A. M. *et al.* Neutralizing antibodies against EGF and ErbB-2/*neu* receptor tyrosine kinases down-regulate VEGF production by tumor cells *in vitro* and *in vivo*: angiogenic implications for signal transduction therapy of solid tumors. *Am. J. Pathol.* **151**, 1523–1530 (1997).
90. Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D. & Jain, R. K. Tumor biology: herepentin acts as an anti-angiogenic cocktail. *Nature* **416**, 279–280 (2002).
91. Asahara, T. *et al.* Isolation of putative progenitor endothelial cells for angiogenesis. *Science* **275**, 964–967 (1997).
92. Garcia-Barros, M. *et al.* Tumor response to radiotherapy regulated by endothelial cell apoptosis. *Science* **300**, 1155–1159 (2003).
93. Rafii, S., Lyden, D., Benezra, R., Hattori, K. & Heissig, B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? *Nature Rev. Cancer* **2**, 826–835 (2002).
94. Ruzinova, M. B. *et al.* Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. *Cancer Cell* **4**, 277–289 (2003).
95. Sikder, H. *et al.* Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors. *Cancer Cell* **4**, 291–299 (2003).
96. Takahashi, T. *et al.* Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. *Nature Med.* **5**, 434–438 (1999).
97. Heeschen, C. *et al.* Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. *Blood* **102**, 1340–1346 (2003).
98. Lyden, D. *et al.* Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. *Nature Med.* **7**, 1194–1201 (2001).
99. Muta, M. *et al.* Impact of vasculoclonal on solid tumor growth in a rat model. *Oncol. Rep.* **10**, 1213–1218 (2003).
100. Brower, V. Epoetin for cancer patients: a boon or a danger? *J. Natl. Cancer Inst.* **95**, 1820–1821 (2004).
101. Masferrer, J. L. *et al.* Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. *Cancer Res.* **60**, 1306–1311 (2000).
102. Gately, S. & Kerbel, R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. *Prog. Exp. Tumor Res.* **37**, 179–192 (2003).
103. DiPaola, R. S., Durivage, H. J. & Kamen, B. A. High time for low-dose prospective clinical trials. *Cancer* **98**, 1559–1561 (2003).
104. Mancuso, P. *et al.* Circulating endothelial cells in preclinical cancer models and in cancer patients: origin, kinetics and viability after conventional-dose or metronomic chemotherapy. *Proc. Am. Assoc. Cancer Res.* A2051 (2003).
105. Willett, C. G. *et al.* Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. *Nature Med.* **10**, 145–147 (2004).
106. Ben-Efraim, S. Immunomodulating anticancer alkylating drugs: targets and mechanisms of activity. *Curr. Drug Targets* **2**, 197–212 (2001).
107. Matar, P., Guillermo, G., Celoria, C., Font, M. T. & Scharovsky, O. G. Antimetastatic effect of a single-low dose of cyclophosphamide on a rat lymphoma. *J. Exp. Clin. Cancer Res.* **14**, 59–63 (1995).
108. Hermans, I. F., Chong, T. W., Palmowski, M. J., Harris, A. L. & Cerundolo, V. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. *Cancer Res.* **63**, 8408–8413 (2003).
- An important study illustrating the potential benefits of combining a non-immunosuppressive metronomic weekly cyclophosphamide regimen with an immunotherapeutic approach to treat cancer. This circumvents the contra-indicated use of immunosuppressive MTD cytotoxic drug regimens with immunotherapy.**
109. Dunussi-Joannopoulos, K. The combination of chemotherapy and systemic immunotherapy and the concept of cure in murine leukemia and lymphoma. *Leuk. Lymphoma* **43**, 2075–2082 (2002).
110. Wu, L. & Tannock, I. F. Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-fluorouracil. *Cancer Res.* **63**, 2134–2138 (2003).
111. Rubie, H. *et al.* Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy. *Br. J. Cancer* **89**, 1605–1609 (2003).
112. Azzarelli, A. *et al.* Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibrosarcoma. *Cancer* **92**, 1259–1264 (2001).

113. Lamont, E. B. & Schilsky, R. L. The oral fluoropyrimidines in cancer chemotherapy. *Clin. Cancer Res.* **5**, 2289–2296 (1999).

114. Hoff, P. M., Pazdur, R., Benner, S. E. & Canetta, R. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. *Anticancer Drugs* **9**, 479–490 (1998).

115. Friedman, M. Of what value is uracil/tegafur plus leucovorin to colorectal cancer patients? *J. Clin. Oncol.* **20**, 3574–3575 (2002).

116. Kato, H. *et al.* A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. *N. Engl. J. Med.* **350**, 1713–1721 (2004).

The results of an important Phase III trial to test adjuvant chemotherapy in patients with early stage lung cancer using a 5-fluoruracil prodrug called uracil plus tegafur. This drug was administered orally at low dose every day for two years, with no breaks. This could be an example, in retrospect, of a metronomic chemotherapy regimen with validated efficacy.

117. Yonekura, K. *et al.* UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. *Clin. Cancer Res.* **5**, 2185–2191 (1999).

118. Newlands, E. S., Stevens, M. F., Wedge, S. R., Wheelhouse, R. T. & Brock, C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. *Cancer Treat. Rev.* **23**, 35–61 (1997).

119. Kurzen, H., Schmitt, S., Naher, H. & Mohler, T. Inhibition of angiogenesis by non-toxic doses of temozolomide. *Anticancer Drugs* **14**, 515–522 (2004).

120. Niitsu, N. & Umeda, M. Evaluation of long-term daily administration of oral low-dose etoposide in elderly patients with relapsing or refractory non-Hodgkin's lymphoma. *Am. J. Clin. Oncol.* **20**, 311–314 (1997).

121. Braybrooke, J. P. *et al.* A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. *Clin. Cancer Res.* **6**, 4697–4704 (2000).

122. Danson, S. *et al.* Randomized phase II study of temozolomide given every 8 hours or daily with either interferon α -2b or thalidomide in metastatic malignant melanoma. *J. Clin. Oncol.* **21**, 2551–2557 (2003).

123. Hwu, W. J. *et al.* Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. *J. Clin. Oncol.* **21**, 3351–3356 (2003).

124. Malingre, M. M., Beijnen, J. H. & Schellens, J. H. Oral delivery of taxanes. *Invest. New Drugs* **19**, 155–162 (2001).

125. Pastorino, F. *et al.* Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. *Cancer Res.* **63**, 7400–7409 (2003).

126. Mauceri, H. J. *et al.* Combined effects of angiostatin and ionizing radiation in antitumor therapy. *Nature* **394**, 287–291 (1998).

127. Wachsberger, P., Burd, R. & Dicker, A. P. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. *Clin. Cancer Res.* **9**, 1957–1971 (2003).

128. Kaban, L. B. *et al.* Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon α -2a. *Pediatrics* **103**, 1145–1149 (1999).

129. Ezekowitz, R. A., Mulliken, J. B. & Folkman, J. Interferon α -2a therapy for life-threatening hemangiomas of infancy. *N. Engl. J. Med.* **326**, 1456–1463 (1992).

130. Slaton, J. W., Perrotte, P., Inoue, K., Dinney, C. P. & Fidler, I. J. Interferon- α -mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. *Clin. Cancer Res.* **5**, 2726–2734 (1999).

131. Eisenhauer, E. A. Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture. *Ann. Oncol.* **9**, 1047–1052 (1998).

132. Cristofanilli, M., Charnsangavej, C. & Hortobagyi, G. N. Angiogenesis modulation in cancer research: novel clinical approaches. *Nature Rev. Drug Discov.* **1**, 415–426 (2002).

133. Wolf, W., Presant, C. A., Waluch, V. & Le Berthon, B. J. Response to anticancer treatment with Docetaxel (DOC) administered every 3 weeks (Q3w) and weekly (Q1w) is associated with functional assessment of changes in tumoral blood flow/perfusion. *Proc. Am. Assoc. Cancer Res.* A5343 (2003).

134. Morgan, B. *et al.* Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. *J. Clin. Oncol.* **21**, 3955–3964 (2003).

135. Rabascio, C. *et al.* Assessing tumour angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. *Cancer Res.* (in the press).

136. Su, Y. B. *et al.* Selective CD4⁺ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. *J. Clin. Oncol.* **22**, 610–616 (2004).

137. Kaur, H. & Budd, G. T. Metronomic therapy for breast cancer. *Curr. Oncol. Rep.* **6**, 49–52 (2004).

138. Kieran, M. W. Anti-angiogenic chemotherapy in central nervous system tumors. *Cancer Treat. Res.* **117**, 337–349 (2004).

139. Gluck, S. *et al.* Metronomic therapy in recurrent and metastatic chemo-resistant SCCCHN: Data from a pilot study. *Proc. Am. Soc. Clin. Oncol.* **22**, A2066 (2003).

140. Buckstein, R. *et al.* High dose celecoxib and low dose cyclophosphamide for relapsed aggressive histology NHL. *Proc. Am. Soc. Clin. Oncol.* **22**, A827 (2003).

141. Bjarnason, G. A. *et al.* Phase II trial of continuous low dose cyclophosphamide and celecoxib in patients with progressing advanced renal cell carcinoma (RCC). *Proc. Am. Soc. Clin. Oncol.* **22**, A1717 (2003).

142. Bergers, G. & Hanahan, D. Combining antiangiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice. *Cold Spring Harb. Symp. Quant. Biol.* **67**, 293–300.

Acknowledgements

We are grateful to C. Cheng for her excellent secretarial and editorial assistance. We thank U. Emmenegger for critical reading of the manuscript. R.S.K. is a Canada Research Chair in Molecular Medicine whose research is supported by grants from the National Institutes of Health (USA), the National Cancer Institute of Canada, and the Canadian Institutes of Health Research. B.A.K. is an American Cancer Society Clinical Research professor. This review is dedicated to T. Browder, whose pioneering studies in the laboratory of J. Folkman opened up the area of anti-angiogenic metronomic chemotherapy.

Competing interests statement

The authors declare competing financial interests: see [web version](#) for details.

 Online links

DATABASES

The following terms in this article are linked online to:

Cancer.gov: <http://cancer.gov/>
acute lymphoblastic leukaemia | breast cancer | colorectal cancer | melanoma | neuroblastoma | non-Hodgkin's lymphoma | non-small-cell lung cancer | ovarian cancer | prostate cancer | rhabdomyosarcoma
Entrez Gene: <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene>
angiopoietin 1 | bFGF | CD36 | COX2 | ERBB2 | G-CSF | IFN- α | MDR1 | TSP1 | VE-cadherin | VEGF | VEGFR2
OMIM: <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM>
Wilms' tumour

FURTHER INFORMATION

Angiogenesis Foundation: www.angio.org
Access to this interactive links box is free online.